nodes	percent_of_prediction	percent_of_DWPC	metapath
Albendazole—CYP1A2—Sorafenib—thyroid cancer	0.113	0.243	CbGbCtD
Albendazole—ABCB1—Sorafenib—thyroid cancer	0.0988	0.212	CbGbCtD
Albendazole—CYP3A4—Vandetanib—thyroid cancer	0.0982	0.211	CbGbCtD
Albendazole—ABCB1—Doxorubicin—thyroid cancer	0.06	0.129	CbGbCtD
Albendazole—CYP3A4—Sorafenib—thyroid cancer	0.0592	0.127	CbGbCtD
Albendazole—CYP3A4—Doxorubicin—thyroid cancer	0.0359	0.0772	CbGbCtD
Albendazole—TUBB4B—Afatinib—Vandetanib—thyroid cancer	0.0222	1	CbGdCrCtD
Albendazole—TUBA1A—neck—thyroid cancer	0.0138	0.154	CbGeAlD
Albendazole—Alopecia reversible—Epirubicin—thyroid cancer	0.0134	0.052	CcSEcCtD
Albendazole—Alopecia reversible—Doxorubicin—thyroid cancer	0.0124	0.0481	CcSEcCtD
Albendazole—TUBA1A—Loss of Nlp from mitotic centrosomes—PCM1—thyroid cancer	0.011	0.0665	CbGpPWpGaD
Albendazole—TUBA1A—saliva-secreting gland—thyroid cancer	0.0107	0.12	CbGeAlD
Albendazole—TUBA1A—Centrosome maturation—PCM1—thyroid cancer	0.00973	0.0589	CbGpPWpGaD
Albendazole—TUBA1A—Regulation of PLK1 Activity at G2/M Transition—PCM1—thyroid cancer	0.00893	0.0541	CbGpPWpGaD
Albendazole—TUBA1A—trachea—thyroid cancer	0.00828	0.0927	CbGeAlD
Albendazole—Neutropenia—Vandetanib—thyroid cancer	0.00717	0.0278	CcSEcCtD
Albendazole—TUBB4B—saliva-secreting gland—thyroid cancer	0.00716	0.0801	CbGeAlD
Albendazole—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00678	0.0263	CcSEcCtD
Albendazole—TUBA1A—G2/M Transition—PCM1—thyroid cancer	0.00671	0.0406	CbGpPWpGaD
Albendazole—TUBB4B—Loss of Nlp from mitotic centrosomes—PCM1—thyroid cancer	0.00663	0.0402	CbGpPWpGaD
Albendazole—TUBA1A—Mitotic G2-G2/M phases—PCM1—thyroid cancer	0.00662	0.0401	CbGpPWpGaD
Albendazole—TUBA1A—thyroid gland—thyroid cancer	0.00655	0.0733	CbGeAlD
Albendazole—Renal failure acute—Sorafenib—thyroid cancer	0.00648	0.0251	CcSEcCtD
Albendazole—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00647	0.0251	CcSEcCtD
Albendazole—Urinary tract disorder—Vandetanib—thyroid cancer	0.00606	0.0235	CcSEcCtD
Albendazole—Urethral disorder—Vandetanib—thyroid cancer	0.00602	0.0233	CcSEcCtD
Albendazole—TUBB4B—Centrosome maturation—PCM1—thyroid cancer	0.00588	0.0356	CbGpPWpGaD
Albendazole—TUBA1A—head—thyroid cancer	0.00581	0.0651	CbGeAlD
Albendazole—Erythema multiforme—Vandetanib—thyroid cancer	0.0058	0.0225	CcSEcCtD
Albendazole—TUBB4B—trachea—thyroid cancer	0.00552	0.0618	CbGeAlD
Albendazole—Alopecia—Vandetanib—thyroid cancer	0.00542	0.021	CcSEcCtD
Albendazole—TUBB4B—Regulation of PLK1 Activity at G2/M Transition—PCM1—thyroid cancer	0.00539	0.0327	CbGpPWpGaD
Albendazole—Neutropenia—Sorafenib—thyroid cancer	0.00484	0.0187	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00457	0.0177	CcSEcCtD
Albendazole—TUBA1A—Loss of Nlp from mitotic centrosomes—CDK1—thyroid cancer	0.00455	0.0275	CbGpPWpGaD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00452	0.0175	CcSEcCtD
Albendazole—TUBB4B—thyroid gland—thyroid cancer	0.00437	0.0489	CbGeAlD
Albendazole—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00436	0.0169	CcSEcCtD
Albendazole—Thrombocytopenia—Vandetanib—thyroid cancer	0.00427	0.0165	CcSEcCtD
Albendazole—Skin disorder—Vandetanib—thyroid cancer	0.00424	0.0164	CcSEcCtD
Albendazole—Urinary tract disorder—Sorafenib—thyroid cancer	0.00409	0.0158	CcSEcCtD
Albendazole—TUBA1A—lymph node—thyroid cancer	0.00407	0.0456	CbGeAlD
Albendazole—Urethral disorder—Sorafenib—thyroid cancer	0.00406	0.0157	CcSEcCtD
Albendazole—TUBB4B—G2/M Transition—PCM1—thyroid cancer	0.00405	0.0245	CbGpPWpGaD
Albendazole—TUBA1A—Centrosome maturation—CDK1—thyroid cancer	0.00403	0.0244	CbGpPWpGaD
Albendazole—TUBB4B—Mitotic G2-G2/M phases—PCM1—thyroid cancer	0.00399	0.0242	CbGpPWpGaD
Albendazole—Erythema multiforme—Sorafenib—thyroid cancer	0.00391	0.0152	CcSEcCtD
Albendazole—TUBB4B—head—thyroid cancer	0.00388	0.0434	CbGeAlD
Albendazole—Immune system disorder—Sorafenib—thyroid cancer	0.00374	0.0145	CcSEcCtD
Albendazole—TUBA1A—Regulation of PLK1 Activity at G2/M Transition—CDK1—thyroid cancer	0.0037	0.0224	CbGpPWpGaD
Albendazole—TUBA1A—p73 transcription factor network—CDK1—thyroid cancer	0.0037	0.0224	CbGpPWpGaD
Albendazole—Alopecia—Sorafenib—thyroid cancer	0.00366	0.0142	CcSEcCtD
Albendazole—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00357	0.0138	CcSEcCtD
Albendazole—Body temperature increased—Vandetanib—thyroid cancer	0.00345	0.0134	CcSEcCtD
Albendazole—Abdominal pain—Vandetanib—thyroid cancer	0.00345	0.0134	CcSEcCtD
Albendazole—Leukopenia—Sorafenib—thyroid cancer	0.00323	0.0125	CcSEcCtD
Albendazole—CYP1A1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00315	0.0191	CbGpPWpGaD
Albendazole—CYP1A1—trachea—thyroid cancer	0.00309	0.0346	CbGeAlD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00308	0.0186	CbGpPWpGaD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00305	0.0118	CcSEcCtD
Albendazole—Dizziness—Vandetanib—thyroid cancer	0.00288	0.0112	CcSEcCtD
Albendazole—Thrombocytopenia—Sorafenib—thyroid cancer	0.00288	0.0112	CcSEcCtD
Albendazole—Aplastic anaemia—Epirubicin—thyroid cancer	0.00286	0.0111	CcSEcCtD
Albendazole—Skin disorder—Sorafenib—thyroid cancer	0.00286	0.0111	CcSEcCtD
Albendazole—TUBA1A—G2/M Transition—CDK1—thyroid cancer	0.00278	0.0168	CbGpPWpGaD
Albendazole—Vomiting—Vandetanib—thyroid cancer	0.00277	0.0107	CcSEcCtD
Albendazole—Rash—Vandetanib—thyroid cancer	0.00275	0.0107	CcSEcCtD
Albendazole—Dermatitis—Vandetanib—thyroid cancer	0.00275	0.0106	CcSEcCtD
Albendazole—TUBB4B—Loss of Nlp from mitotic centrosomes—CDK1—thyroid cancer	0.00275	0.0166	CbGpPWpGaD
Albendazole—TUBA1A—Mitotic G2-G2/M phases—CDK1—thyroid cancer	0.00274	0.0166	CbGpPWpGaD
Albendazole—Headache—Vandetanib—thyroid cancer	0.00273	0.0106	CcSEcCtD
Albendazole—TUBB4B—lymph node—thyroid cancer	0.00271	0.0304	CbGeAlD
Albendazole—Aplastic anaemia—Doxorubicin—thyroid cancer	0.00265	0.0103	CcSEcCtD
Albendazole—Nausea—Vandetanib—thyroid cancer	0.00259	0.01	CcSEcCtD
Albendazole—CYP1A2—thyroid gland—thyroid cancer	0.00248	0.0277	CbGeAlD
Albendazole—CYP1A1—thyroid gland—thyroid cancer	0.00245	0.0274	CbGeAlD
Albendazole—TUBB4B—Centrosome maturation—CDK1—thyroid cancer	0.00243	0.0147	CbGpPWpGaD
Albendazole—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00241	0.00932	CcSEcCtD
Albendazole—Renal failure acute—Epirubicin—thyroid cancer	0.0024	0.00928	CcSEcCtD
Albendazole—Urticaria—Sorafenib—thyroid cancer	0.00234	0.00905	CcSEcCtD
Albendazole—Abdominal pain—Sorafenib—thyroid cancer	0.00233	0.00901	CcSEcCtD
Albendazole—Body temperature increased—Sorafenib—thyroid cancer	0.00233	0.00901	CcSEcCtD
Albendazole—TUBB4B—Regulation of PLK1 Activity at G2/M Transition—CDK1—thyroid cancer	0.00223	0.0135	CbGpPWpGaD
Albendazole—Renal failure acute—Doxorubicin—thyroid cancer	0.00222	0.00859	CcSEcCtD
Albendazole—CYP1A1—head—thyroid cancer	0.00217	0.0243	CbGeAlD
Albendazole—Hypersensitivity—Sorafenib—thyroid cancer	0.00217	0.0084	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.00213	0.0129	CbGpPWpGaD
Albendazole—Liver function test abnormal—Epirubicin—thyroid cancer	0.00204	0.00791	CcSEcCtD
Albendazole—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00203	0.0123	CbGpPWpGaD
Albendazole—CYP1A2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00201	0.0122	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00196	0.0119	CbGpPWpGaD
Albendazole—Dizziness—Sorafenib—thyroid cancer	0.00194	0.00754	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—PCM1—thyroid cancer	0.00191	0.0116	CbGpPWpGaD
Albendazole—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00189	0.00732	CcSEcCtD
Albendazole—Vomiting—Sorafenib—thyroid cancer	0.00187	0.00725	CcSEcCtD
Albendazole—Rash—Sorafenib—thyroid cancer	0.00185	0.00719	CcSEcCtD
Albendazole—Dermatitis—Sorafenib—thyroid cancer	0.00185	0.00718	CcSEcCtD
Albendazole—Headache—Sorafenib—thyroid cancer	0.00184	0.00714	CcSEcCtD
Albendazole—Pancytopenia—Epirubicin—thyroid cancer	0.00182	0.00703	CcSEcCtD
Albendazole—Neutropenia—Epirubicin—thyroid cancer	0.00179	0.00693	CcSEcCtD
Albendazole—Nausea—Sorafenib—thyroid cancer	0.00175	0.00677	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00169	0.00655	CcSEcCtD
Albendazole—Pancytopenia—Doxorubicin—thyroid cancer	0.00168	0.00651	CcSEcCtD
Albendazole—TUBB4B—G2/M Transition—CDK1—thyroid cancer	0.00168	0.0102	CbGpPWpGaD
Albendazole—TUBB4B—Orphan transporters—RXRA—thyroid cancer	0.00166	0.0101	CbGpPWpGaD
Albendazole—Neutropenia—Doxorubicin—thyroid cancer	0.00165	0.00641	CcSEcCtD
Albendazole—TUBB4B—Mitotic G2-G2/M phases—CDK1—thyroid cancer	0.00165	0.01	CbGpPWpGaD
Albendazole—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00161	0.00625	CcSEcCtD
Albendazole—ABCB1—trachea—thyroid cancer	0.00161	0.018	CbGeAlD
Albendazole—Agranulocytosis—Epirubicin—thyroid cancer	0.00159	0.00616	CcSEcCtD
Albendazole—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.00156	0.00606	CcSEcCtD
Albendazole—Hepatitis—Epirubicin—thyroid cancer	0.00153	0.00593	CcSEcCtD
Albendazole—CYP1A1—lymph node—thyroid cancer	0.00152	0.017	CbGeAlD
Albendazole—Urinary tract disorder—Epirubicin—thyroid cancer	0.00151	0.00586	CcSEcCtD
Albendazole—Urethral disorder—Epirubicin—thyroid cancer	0.0015	0.00581	CcSEcCtD
Albendazole—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00149	0.00578	CcSEcCtD
Albendazole—Agranulocytosis—Doxorubicin—thyroid cancer	0.00147	0.0057	CcSEcCtD
Albendazole—Erythema multiforme—Epirubicin—thyroid cancer	0.00145	0.00561	CcSEcCtD
Albendazole—CYP1A1—Metapathway biotransformation—CHST14—thyroid cancer	0.00143	0.00868	CbGpPWpGaD
Albendazole—Hepatitis—Doxorubicin—thyroid cancer	0.00142	0.00549	CcSEcCtD
Albendazole—Urinary tract disorder—Doxorubicin—thyroid cancer	0.0014	0.00542	CcSEcCtD
Albendazole—Urethral disorder—Doxorubicin—thyroid cancer	0.00139	0.00538	CcSEcCtD
Albendazole—Immune system disorder—Epirubicin—thyroid cancer	0.00138	0.00536	CcSEcCtD
Albendazole—Alopecia—Epirubicin—thyroid cancer	0.00135	0.00524	CcSEcCtD
Albendazole—Erythema multiforme—Doxorubicin—thyroid cancer	0.00134	0.00519	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—TPR—thyroid cancer	0.0013	0.00789	CbGpPWpGaD
Albendazole—ABCB1—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.0013	0.00786	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—PCM1—thyroid cancer	0.00129	0.0078	CbGpPWpGaD
Albendazole—Immune system disorder—Doxorubicin—thyroid cancer	0.00128	0.00496	CcSEcCtD
Albendazole—ABCB1—thyroid gland—thyroid cancer	0.00127	0.0142	CbGeAlD
Albendazole—Alopecia—Doxorubicin—thyroid cancer	0.00125	0.00485	CcSEcCtD
Albendazole—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00121	0.00735	CbGpPWpGaD
Albendazole—Vertigo—Epirubicin—thyroid cancer	0.0012	0.00464	CcSEcCtD
Albendazole—Leukopenia—Epirubicin—thyroid cancer	0.00119	0.00462	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—TPR—thyroid cancer	0.00117	0.00706	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—CP—thyroid cancer	0.00116	0.007	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—PCM1—thyroid cancer	0.00115	0.00698	CbGpPWpGaD
Albendazole—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.00115	0.00697	CbGpPWpGaD
Albendazole—ABCB1—head—thyroid cancer	0.00113	0.0126	CbGeAlD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00113	0.00436	CcSEcCtD
Albendazole—Vertigo—Doxorubicin—thyroid cancer	0.00111	0.00429	CcSEcCtD
Albendazole—Leukopenia—Doxorubicin—thyroid cancer	0.0011	0.00427	CcSEcCtD
Albendazole—Thrombocytopenia—Epirubicin—thyroid cancer	0.00106	0.00412	CcSEcCtD
Albendazole—Skin disorder—Epirubicin—thyroid cancer	0.00106	0.00409	CcSEcCtD
Albendazole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00104	0.00404	CcSEcCtD
Albendazole—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000985	0.00382	CcSEcCtD
Albendazole—CYP1A1—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000983	0.00595	CbGpPWpGaD
Albendazole—Skin disorder—Doxorubicin—thyroid cancer	0.000977	0.00379	CcSEcCtD
Albendazole—CYP1A2—Metapathway biotransformation—CHST14—thyroid cancer	0.000914	0.00553	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	0.000907	0.00549	CbGpPWpGaD
Albendazole—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000889	0.00344	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000883	0.00535	CbGpPWpGaD
Albendazole—Urticaria—Epirubicin—thyroid cancer	0.000864	0.00335	CcSEcCtD
Albendazole—Abdominal pain—Epirubicin—thyroid cancer	0.000859	0.00333	CcSEcCtD
Albendazole—Body temperature increased—Epirubicin—thyroid cancer	0.000859	0.00333	CcSEcCtD
Albendazole—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000822	0.00319	CcSEcCtD
Albendazole—Hypersensitivity—Epirubicin—thyroid cancer	0.000801	0.0031	CcSEcCtD
Albendazole—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.0008	0.00484	CbGpPWpGaD
Albendazole—Urticaria—Doxorubicin—thyroid cancer	0.000799	0.0031	CcSEcCtD
Albendazole—CYP1A1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000797	0.00482	CbGpPWpGaD
Albendazole—Abdominal pain—Doxorubicin—thyroid cancer	0.000795	0.00308	CcSEcCtD
Albendazole—Body temperature increased—Doxorubicin—thyroid cancer	0.000795	0.00308	CcSEcCtD
Albendazole—TUBA1A—Cell Cycle—CDK1—thyroid cancer	0.00079	0.00478	CbGpPWpGaD
Albendazole—ABCB1—lymph node—thyroid cancer	0.000789	0.00883	CbGeAlD
Albendazole—TUBB4B—Cell Cycle, Mitotic—TPR—thyroid cancer	0.000787	0.00477	CbGpPWpGaD
Albendazole—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000781	0.00473	CbGpPWpGaD
Albendazole—Hypersensitivity—Doxorubicin—thyroid cancer	0.000741	0.00287	CcSEcCtD
Albendazole—Dizziness—Epirubicin—thyroid cancer	0.000719	0.00279	CcSEcCtD
Albendazole—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000705	0.00427	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TPR—thyroid cancer	0.000704	0.00426	CbGpPWpGaD
Albendazole—Vomiting—Epirubicin—thyroid cancer	0.000691	0.00268	CcSEcCtD
Albendazole—Rash—Epirubicin—thyroid cancer	0.000685	0.00266	CcSEcCtD
Albendazole—Dermatitis—Epirubicin—thyroid cancer	0.000685	0.00265	CcSEcCtD
Albendazole—Headache—Epirubicin—thyroid cancer	0.000681	0.00264	CcSEcCtD
Albendazole—Dizziness—Doxorubicin—thyroid cancer	0.000665	0.00258	CcSEcCtD
Albendazole—TUBB4B—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000646	0.00391	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—CP—thyroid cancer	0.000646	0.00391	CbGpPWpGaD
Albendazole—Nausea—Epirubicin—thyroid cancer	0.000646	0.0025	CcSEcCtD
Albendazole—Vomiting—Doxorubicin—thyroid cancer	0.000639	0.00248	CcSEcCtD
Albendazole—TUBB4B—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000635	0.00385	CbGpPWpGaD
Albendazole—Rash—Doxorubicin—thyroid cancer	0.000634	0.00246	CcSEcCtD
Albendazole—Dermatitis—Doxorubicin—thyroid cancer	0.000634	0.00246	CcSEcCtD
Albendazole—Headache—Doxorubicin—thyroid cancer	0.00063	0.00244	CcSEcCtD
Albendazole—CYP1A2—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000627	0.00379	CbGpPWpGaD
Albendazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000623	0.00377	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—RXRA—thyroid cancer	0.000605	0.00366	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000604	0.00366	CbGpPWpGaD
Albendazole—Nausea—Doxorubicin—thyroid cancer	0.000597	0.00232	CcSEcCtD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—RXRA—thyroid cancer	0.000592	0.00359	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TERT—thyroid cancer	0.000569	0.00345	CbGpPWpGaD
Albendazole—CYP1A1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000565	0.00342	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	0.000565	0.00342	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	0.00054	0.00327	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CDK1—thyroid cancer	0.000533	0.00323	CbGpPWpGaD
Albendazole—CYP1A2—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000508	0.00308	CbGpPWpGaD
Albendazole—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000484	0.00293	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000483	0.00293	CbGpPWpGaD
Albendazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000481	0.00291	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CDK1—thyroid cancer	0.000477	0.00289	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.00047	0.00284	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00045	0.00272	CbGpPWpGaD
Albendazole—CYP1A1—Biological oxidations—RXRA—thyroid cancer	0.000423	0.00256	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—RXRA—thyroid cancer	0.000408	0.00247	CbGpPWpGaD
Albendazole—TUBB4B—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000406	0.00246	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000404	0.00245	CbGpPWpGaD
Albendazole—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000392	0.00237	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—thyroid cancer	0.000385	0.00233	CbGpPWpGaD
Albendazole—CYP1A1—PPARA activates gene expression—PPARG—thyroid cancer	0.000382	0.00231	CbGpPWpGaD
Albendazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—thyroid cancer	0.000374	0.00226	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000368	0.00223	CbGpPWpGaD
Albendazole—CYP1A2—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00036	0.00218	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TERT—thyroid cancer	0.000344	0.00208	CbGpPWpGaD
Albendazole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000344	0.00208	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—CCND1—thyroid cancer	0.000329	0.00199	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—MINPP1—thyroid cancer	0.000311	0.00188	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000311	0.00188	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000299	0.00181	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000287	0.00174	CbGpPWpGaD
Albendazole—CYP1A2—Biological oxidations—RXRA—thyroid cancer	0.00027	0.00163	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—NDUFA13—thyroid cancer	0.000264	0.0016	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000258	0.00156	CbGpPWpGaD
Albendazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	0.000258	0.00156	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—CHST14—thyroid cancer	0.000249	0.0015	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—MINPP1—thyroid cancer	0.000248	0.0015	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle, Mitotic—CCND1—thyroid cancer	0.000222	0.00135	CbGpPWpGaD
Albendazole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000219	0.00133	CbGpPWpGaD
Albendazole—TUBA1A—Cell Cycle—TP53—thyroid cancer	0.000217	0.00131	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—NDUFA13—thyroid cancer	0.000211	0.00128	CbGpPWpGaD
Albendazole—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000208	0.00126	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—HPGD—thyroid cancer	0.0002	0.00121	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—CCND1—thyroid cancer	0.000199	0.0012	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—CHST14—thyroid cancer	0.000199	0.0012	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—MINPP1—thyroid cancer	0.000198	0.0012	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000196	0.00119	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000196	0.00119	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000193	0.00117	CbGpPWpGaD
Albendazole—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	0.000182	0.0011	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—NDUFA13—thyroid cancer	0.000169	0.00102	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000163	0.000984	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—HPGD—thyroid cancer	0.00016	0.000969	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—CHST14—thyroid cancer	0.000158	0.00096	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	0.000154	0.000935	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000153	0.000926	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000147	0.000889	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	0.000139	0.000845	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	0.000135	0.000815	CbGpPWpGaD
Albendazole—TUBB4B—Cell Cycle—TP53—thyroid cancer	0.000131	0.000793	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.00013	0.000788	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—HPGD—thyroid cancer	0.000128	0.000773	CbGpPWpGaD
Albendazole—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000123	0.000747	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000122	0.000741	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—TPR—thyroid cancer	0.000115	0.000697	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	0.000113	0.000685	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000104	0.000627	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	0.000103	0.000626	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000103	0.000621	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—HPGD—thyroid cancer	9.86e-05	0.000597	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—TPR—thyroid cancer	9.19e-05	0.000556	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	9.19e-05	0.000556	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PRKAR1A—thyroid cancer	9.04e-05	0.000547	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—SLC5A5—thyroid cancer	8.61e-05	0.000522	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	8.07e-05	0.000489	CbGpPWpGaD
Albendazole—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	7.76e-05	0.00047	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—TPR—thyroid cancer	7.34e-05	0.000444	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—RXRA—thyroid cancer	7.24e-05	0.000438	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	7.22e-05	0.000437	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	7.04e-05	0.000426	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—SLC5A5—thyroid cancer	6.88e-05	0.000417	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.54e-05	0.000396	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—RXRA—thyroid cancer	5.78e-05	0.00035	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—TPR—thyroid cancer	5.66e-05	0.000343	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.57e-05	0.000337	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—SLC5A5—thyroid cancer	5.49e-05	0.000333	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.15e-05	0.000312	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—RXRA—thyroid cancer	4.61e-05	0.000279	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PPARG—thyroid cancer	4.57e-05	0.000277	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.49e-05	0.000272	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.24e-05	0.000257	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PPARG—thyroid cancer	3.65e-05	0.000221	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PTGS2—thyroid cancer	3.59e-05	0.000218	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—RXRA—thyroid cancer	3.56e-05	0.000216	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—PTEN—thyroid cancer	3.13e-05	0.00019	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PPARG—thyroid cancer	2.91e-05	0.000176	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PTGS2—thyroid cancer	2.87e-05	0.000174	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—PTEN—thyroid cancer	2.5e-05	0.000152	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PTGS2—thyroid cancer	2.29e-05	0.000139	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PPARG—thyroid cancer	2.25e-05	0.000136	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—PTEN—thyroid cancer	2e-05	0.000121	CbGpPWpGaD
Albendazole—CYP1A1—Metabolism—AKT1—thyroid cancer	1.81e-05	0.000109	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.77e-05	0.000107	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—PTEN—thyroid cancer	1.54e-05	9.34e-05	CbGpPWpGaD
Albendazole—ABCB1—Metabolism—AKT1—thyroid cancer	1.44e-05	8.74e-05	CbGpPWpGaD
Albendazole—CYP1A2—Metabolism—AKT1—thyroid cancer	1.15e-05	6.98e-05	CbGpPWpGaD
Albendazole—CYP3A4—Metabolism—AKT1—thyroid cancer	8.89e-06	5.38e-05	CbGpPWpGaD
